Obstructing esophageal cancer produces severe dysphagia with ensuing death within 90 days. Palliation is possible with modalities like stent placement, laser, and photodynamic therapy. However, these treatments have a high rate of complications, and the overall mortality is not altered. A new alternative treatment evaluated in this study is endoscopic intratumoral injection with cisplatin/epinephrine (CDDP/epi) gel. CDDP/epi gel injections were administered weekly for 3 to 8 weeks in nine patients, median age, 72 years; mean tumor volume (±SEM), 41.44 (±22.4) cm3. Eight patients had stage IV, and one had stage III esophageal carcinoma. The mean dysphagia score (±SEM) was 3.5 (±0.17). All patients were followed up until death. Dysphagia resolved in eight patients with reduction in mean dysphagia score (±SEM) from 3.5 (±0.17) to 0.75 (±0.28; p = 0.005). Tumor volume was reduced by 75% in one patient and by 50% in two patients. The median survival was 4 months. The longest follow-up has been 15 months (458 days). In this pilot study, intratumoral injection of CDDP/epi gel restored swallowing in eight of nine patients and was an effective and safe outpatient treatment in patients with obstructive esophageal cancer.
|Original language||English (US)|
|Number of pages||7|
|Journal||American Journal of Clinical Oncology: Cancer Clinical Trials|
|State||Published - Dec 1 2000|
- Esophageal neoplasms
ASJC Scopus subject areas
- Cancer Research